Novo Nordisk and AWS Open London AI Hub
The strategic partnership will use agentic AI to accelerate drug discovery for chronic disease treatments.
A modern pharmaceutical research facility interior in London where researchers work with digital molecular models on large screens.
Photo: Kronos News
Novo Nordisk and Amazon Web Services (AWS) have launched a new co-innovation hub in London [1][2]. This strategic partnership aims to accelerate the discovery of treatments for chronic diseases [1]. The facility will focus on reducing drug development timelines by integrating agentic AI into the research process [2][3].
The collaboration combines Novo Nordisk’s pharmaceutical expertise with AWS’s cloud and machine learning infrastructure [2]. Researchers intend to use autonomous AI agents to manage complex biological data [3]. This approach could potentially streamline clinical trial design and molecular analysis [1][3].
London was selected as the location to leverage the city’s dense concentration of life sciences and technology talent [1]. Both companies stated that the hub represents a significant commitment to long-term digital transformation in healthcare [2].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
Related stories
View all
About the author
Kronos News Desk covers news and editorial analysis for Kronos News.